Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | PTPRB | P23467 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 3/20 | 0.32 |
| ▸ | MME | P08473 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL452544 | 0.89 | ALDH1A1 (0.41) | ALDH1A1LMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL11738530 | 0.86 | ALDH1A1 (0.36) | ALDH1A1LMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5227219 | 0.83 | TSHR (0.32) | LMNASMN1; SMN2TSHRCYP3A4USP2 | |
| SCHEMBL1973010 | 0.82 | GRIK1 (0.40) | ALDH1A1LMNASMN1; SMN2TSHRCYP3A4 | |
| SCHEMBL4766772 | 0.82 | TSHR (0.42) | ALDH1A1TSHRCYP3A4MAPT | |
| SCHEMBL3607061 | 0.82 | ALDH1A1 (0.39) | ALDH1A1LMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6775939 | 0.82 | LMNA (0.44) | ALDH1A1LMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL7483838 | 0.82 | TSHR (0.31) | TSHR | |
| SCHEMBL17578458 | 0.80 | ALDH1A1 (0.35) | ALDH1A1LMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL10501545 | 0.80 | MEN1 (0.36) | ALDH1A1MEN1KMT2ASMN1; SMN2PTPRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1613606-A4 | METHODS FOR PREPARING 2,3,5,6-SUBSTITUTED 3H-PYRIMIDIN-4-ONES | NPS PHARMA INC (US) | 2008-12-03 | — | — | EP | claimed |
| US-20070161792-A1 | Methods for preparing 2,3,5,6-substituted 3h-pyrimidin-4-ones | NPS PHARMACUETICALS, INC (US) | 2007-07-12 | — | — | US | claimed |
| EP-1613606-A2 | METHODS FOR PREPARING 2,3,5,6-SUBSTITUTED 3H-PYRIMIDIN-4-ONES | NPS PHARMACEUTICALS, INC. (US) | 2006-01-11 | — | — | EP | claimed |
| WO-2004092121-A2 | METHODS FOR PREPARING 2,3,5,6-SUBSTITUTED 3H-PYRIMIDIN-4-ONES | NPS PHARMACEUTICALS, INC. (US) | 2004-10-28 | — | — | WO | claimed |
| CN-105777733-B | A kind of tetrahydric phthalimide class compound and application thereof containing isoxazoline | 沈阳中化农药化工研发有限公司 | 2018-12-14 | — | — | CN | disclosed |
| CN-106536517-A | Isoxazoline-containing uracil compound and application thereof | 沈阳中化农药化工研发有限公司 | 2017-03-22 | — | — | CN | disclosed |
| CN-105777733-A | Isoxazoline-containing tetrahydrophthalimide compound and use thereof | 沈阳中化农药化工研发有限公司 | 2016-07-20 | — | — | CN | disclosed |
| CN-105753853-A | Isoxazoline-containing uracil compound and use thereof | 沈阳中化农药化工研发有限公司 | 2016-07-13 | — | — | CN | disclosed |
| EP-1613606-A4 | METHODS FOR PREPARING 2,3,5,6-SUBSTITUTED 3H-PYRIMIDIN-4-ONES | NPS PHARMA INC (US) | 2008-12-03 | — | — | EP | disclosed |
| US-20070161792-A1 | Methods for preparing 2,3,5,6-substituted 3h-pyrimidin-4-ones | NPS PHARMACUETICALS, INC (US) | 2007-07-12 | — | — | US | disclosed |
| EP-1613606-A2 | METHODS FOR PREPARING 2,3,5,6-SUBSTITUTED 3H-PYRIMIDIN-4-ONES | NPS PHARMACEUTICALS, INC. (US) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004092121-A2 | METHODS FOR PREPARING 2,3,5,6-SUBSTITUTED 3H-PYRIMIDIN-4-ONES | NPS PHARMACEUTICALS, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| EP-0871439-B1 | SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS | AVENTIS PHARMA INC (US) | 2004-03-31 | — | — | EP | disclosed |
| US-6057369-A | USE IN THE TREATMENT OF DISEASE STATES ASSOCIATED WITH PROTEINS THAT MEDIATE CELLULAR ACTIVITY WHICH ARE CAPABLE OF BEING MODULATED BY INHIBITING A MATRIX METALLOPROTEINASE (MMP), TUMOR NECROSIS FACTOR (TNF) OR CYCLIC AMP | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 2000-05-02 | — | — | US | disclosed |
| EP-0871439-A4 | SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS | RHONE POULENC RORER PHARMA (US) | 1999-07-21 | — | — | EP | disclosed |
| EP-0871439-A1 | SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1998-10-21 | — | — | EP | disclosed |
| WO-1997024117-A1 | SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-07-10 | — | — | WO | disclosed |
| US-4245122-A | USING TRICAPRYLMETHYLAMMONIUM CHLORIDE AS A PHASE TRANSFER AGENT | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1981-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161792-A1 | Methods for preparing 2,3,5,6-substituted 3h-pyrimidin-4-ones | TYMP, DPYD, DHFR | ALDH1A1 972/4885LMNA 1356/4885MEN1 1327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.